Combination of intrahepatic TARE and extrahepatic TACE to treat HCC patients with extrahepatic artery supply: A case series.
Extrahepatic artery
HCC
TACE
TARE
Journal
Research in diagnostic and interventional imaging
ISSN: 2772-6525
Titre abrégé: Res Diagn Interv Imaging
Pays: France
ID NLM: 9918574385706676
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
19
10
2023
accepted:
24
02
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
The aim of this study was to report the safety and tumor response rate of combined transarterial radioembolization (TARE) through the intrahepatic arteries and transarterial chemoembolization (TACE) through the extrahepatic feeding arteries (EHFA) in patients with hepatocellular carcinoma (HCC). Patients with HCC, who had both intrahepatic and extrahepatic arterial supply visible on preinterventional multiphase CT and were treated between 2016 and 2021 with a combination of TACE and TARE on the same nodule, were retrospectively included. Epidemiological, clinical, biological, and radiological characteristics were recorded. Safety and tumor response were assessed at 6 months. Nine patients (8 men, median age 62 years [IQR: 54-72 years]) were included. Seven patients had previous treatments on the target nodule (TARE: 5; TACE: 2). The median longest axis (LA) of the lesion was 70 mm (IQR: 60-79 mm). Three patients had portal vein invasion (VP3). The EHFA originated from the right diaphragmatic artery ( The combination of TARE and extrahepatic TACE for HCC with both intrahepatic and extrahepatic arterial supplies seems feasible and safe. Further studies are needed to validate the effectiveness of these preliminary results.
Identifiants
pubmed: 39076578
doi: 10.1016/j.redii.2024.100042
pii: S2772-6525(24)00003-6
pmc: PMC11265365
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100042Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
Authors declare that they do not have any conflict of interest.